- Home
- VVV vs PCVX Comparison
VVV vs PCVX Comparison
Compare VVV & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- PCVX
- Stock Information
- Founded
- VVV 1866
- PCVX 2013
- Country
- VVV United States
- PCVX United States
- Employees
- VVV N/A
- PCVX N/A
- Industry
- VVV Major Chemicals
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- PCVX Health Care
- Exchange
- VVV Nasdaq
- PCVX Nasdaq
- Market Cap
- VVV 4.5B
- PCVX 4.0B
- IPO Year
- VVV 2016
- PCVX 2020
- Fundamental
- Price
- VVV $34.51
- PCVX $41.62
- Analyst Decision
- VVV Buy
- PCVX Strong Buy
- Analyst Count
- VVV 12
- PCVX 8
- Target Price
- VVV $43.00
- PCVX $114.17
- AVG Volume (30 Days)
- VVV 1.7M
- PCVX 2.0M
- Earning Date
- VVV 11-18-2025
- PCVX 11-04-2025
- Dividend Yield
- VVV N/A
- PCVX N/A
- EPS Growth
- VVV 68.45
- PCVX N/A
- EPS
- VVV 2.14
- PCVX N/A
- Revenue
- VVV $1,692,000,000.00
- PCVX N/A
- Revenue This Year
- VVV $6.86
- PCVX N/A
- Revenue Next Year
- VVV $14.28
- PCVX N/A
- P/E Ratio
- VVV $16.31
- PCVX N/A
- Revenue Growth
- VVV 7.53
- PCVX N/A
- 52 Week Low
- VVV $31.02
- PCVX $27.66
- 52 Week High
- VVV $43.74
- PCVX $118.62
- Technical
- Relative Strength Index (RSI)
- VVV 26.01
- PCVX 72.10
- Support Level
- VVV $35.39
- PCVX $31.89
- Resistance Level
- VVV $36.31
- PCVX $43.76
- Average True Range (ATR)
- VVV 0.83
- PCVX 1.88
- MACD
- VVV -0.36
- PCVX 1.04
- Stochastic Oscillator
- VVV 1.43
- PCVX 82.12
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.